Glucose intolerance, diabetes or insulin resistance not linked with pathological features of AD

Glucose intolerance or insulin resistance do not appear to be associated with pathological features of Alzheimer disease (AD) or detection of the accumulation of the brain protein β-amyloid (Αβ), according to a report published by JAMA Neurology.

Glucose intolerance and diabetes mellitus have been proposed as risk factors for the development of AD, but evidence of this has not been consistent, the study background notes.

Madhav Thambisetty, M.D., Ph.D., of the National Institute on Aging, Baltimore, and colleagues investigated the association between glucose intolerance and and brain ?? burden with autopsies and imaging with carbon 11-labeled Pittsburgh Compound B tomography.

"The relationship among diabetes mellitus, insulin and AD is an important area of investigation. However, whether cognitive impairment seen in those with diabetes is mediated by excess pathological features of AD or other related abnormalities, such as vascular disease, remains unclear," the authors comment.

Two groups of participants were involved in the study. One group consisted of 197 participants enrolled in the Baltimore Longitudinal Study of Aging who had two or more oral glucose tolerance tests (OGTT) while they were alive and then underwent a brain autopsy when they died. The second group included 53 living who had two or more OGTTs and underwent imaging.

"In this prospective cohort with multiple assessments of and insulin resistance, measures of glucose and insulin homeostasis are not associated with AD pathology and likely play little role in AD pathogenesis," the study concludes. "Long-term therapeutic trials are important to elucidate this issue."

More information: JAMA Neurol. Published online July 29, 2013. doi:10.1001/jamaneurol.2013.284

add to favorites email to friend print save as pdf

Related Stories

Sucralose affects response to oral glucose load in obese

Jul 02, 2013

(HealthDay)—For obese adults who do not use non-nutritive sweetener (NNS), sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in ...

Telmisartan reverses insulin resistance in mice

Jan 03, 2013

(HealthDay)—Treating mice fed a high-fat diet with telmisartan reverses insulin resistance and glucose intolerance, but only when the peroxisome proliferator-activated receptor-δ (PPAR-δ) gene is present, ...

Recommended for you

Know the brain, and its axons, by the clothes they wear

Apr 18, 2014

(Medical Xpress)—It is widely know that the grey matter of the brain is grey because it is dense with cell bodies and capillaries. The white matter is almost entirely composed of lipid-based myelin, but ...

Turning off depression in the brain

Apr 17, 2014

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Rapid whole-brain imaging with single cell resolution

Apr 17, 2014

A major challenge of systems biology is understanding how phenomena at the cellular scale correlate with activity at the organism level. A concerted effort has been made especially in the brain, as scientists are aiming to ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

gaucho25
not rated yet Jul 29, 2013
A new FDA approved diet pill called Belviq just went on the market. Belviq make people more likely to succeed with weight loss since they feel full more quickly and it reduces food cravings. People who take Belviq with diet and exercise were 2 times more likely to lose 5% body weight and 3 times more likely to lose 10% body weight than the people who just did diet and exercise alone. The label states that if you do not lose 5% of your body weight in 12 weeks then consider stopping. Those that do respond in 12 (about 45% of patients) weeks go on to lose over 10% of their body weight in one year. Losing 22 pounds for a 220 pound person is life changing. So 45% of those taking Belviq lose significant amount of weight.
Belviq has a second mode of action to reduce blood sugar which may end up preventing diabetes in many cases. Diabetics and pre-diabetics who took Belviq, REGARDLESS of weight loss, saw their blood sugar numbers drop by double digit percentages. IE HbA1c -0.9 to -1.2 and fasting glucose feel -27. The cost of medications to reduce HbA1c levels exceeds the cost of Belviq. (seeArena's BloomDM phase III trial) These reductions in diabetic symptoms plus the weight loss at the same time makes Belviq a medical bargain.